Status: Recruiting
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.
Participants needed: 554
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Gustave Roussy, Cancer Campus, Grand ParisUpdated: Jan 20, 2026Locations: 15
Eligibility criteria
Histologically confirmed diagnosis of EC (all grades and the following histologi... [+26]
FIGO Stage IV disease of any histology even if there is no evidence of disease a... [+26]